Table 2. The relationship between clinicopathological parameters and lncRNA-SVUGP2 expression.
| Clinicopathological parameters | Case | LncRNA-SVUGP2 | P | |
|---|---|---|---|---|
| Low | High | |||
| Gender | 0.281 | |||
| Male | 41 | 23 | 18 | |
| Female | 9 | 3 | 6 | |
| Age | 0.57 | |||
| ≤ 60 | 31 | 15 | 16 | |
| > 60 | 19 | 11 | 8 | |
| Tumor size | 0.069 | |||
| ≤ 5 | 16 | 5 | 11 | |
| > 5 | 34 | 21 | 13 | |
| TNM stage | 0.002 | |||
| I–II | 26 | 8 | 18 | |
| III–IV | 24 | 18 | 6 | |
| HBV infection | 0.382 | |||
| No | 11 | 7 | 4 | |
| Yes | 39 | 19 | 20 | |
| Cirrhosis | 0.039 | |||
| No | 14 | 4 | 10 | |
| Yes | 36 | 22 | 14 | |
The level of LncRNA-SVUGP2 was measured in 50 cases of HCC samples by RT-qPCR, and further normalized to GAPDH. These 50 cases were divided into two groups based on the low (26 cases) or high (24 cases) level of lncRNA-SVUGP2 in HCC samples. X2 test and Fisher's exact test test was then used to analyze whether the level of LncRNA-SVUGP2 was significantly changed among patients with different gender, age, tumor size, TNM stage, HBV infection and cirrhosis status.